Bromocrriptine is a drug introduced in the medical therapeutics in 1967, and since then it has been widely used in the treatment of hyperprolactinaemia. In experimental animals and in vitro experiments it inhibits prolactin secretion and the phasic secretion of gonadotrophins, while it does not seem to have an effect on growth hormone, or vasopressin secretion. Various central nervous effects, ...

Negative symptoms are still a major obstacle in the recovery of schizophrenic patients. Many attempts to develop novel drugs affecting negative symptoms of schizophrenia have yielded insignificant results. This study evaluates the effects of bromocriptine, a dopamine agonist, on negative symptoms of schizophrenia utilizing a placebo-controlled crossover double-blind clinical trial. Methodology:...

The pituitary gland has only recently been studied with magnetic resonance (MR) imaging. Initial results suggest MR may have utility in the detection and follow-up of pituitary microadenomas [1]. Of interest, it has been observed that prolactinomas treated with bromocriptine may manifest distinct and diverse MR signal changes [1] . Bromocriptine, a dopamine agonist, has been effective in the sy...

One of the most important causes of anticancer treatment failure is the development of multidrug resistance (MDR). The main characteristics of tumor cells displaying the MDR phenomena are cross-resistance to structurally unrelated cytotoxic drugs having different mechanisms of action and the overexpression of the MDR1 gene, which encodes a transmembrane glycoprotein named P-glycoprotein (P-gp)....

Little is known about the function of microRNAs in prolactinomas treated with bromocriptine. The aim of the study was to explore the microRNAs associated with bromocriptine-treated prolactinomas. Six prolactinoma samples were selected according to whether they received bromocriptine treatment or not before microsurgery, and microRNA expression pro...

A patient with Parkinson's disease, initially treated with bromocriptine and subsequently with cabergoline, developed progressive pleuropulmonary abnormalities during the latter therapy. These lesions even worsened for some weeks after interruption of cabergoline, which may possibly be related to the prolonged action of this drug. Thus cabergoline may cause similar pleuropulmonary abnormalities...

When lactating rats were mated at the post-partum oestrus, treated with a single dose of bromocriptine (2 mg/kg body wt) 7 days later, and killed on Day 11, implantation was induced in 8/24 animals. When the litter was removed at the time of bromocriptine treatment 5/9 rats had implantations compared with 9/10 after litter removal alone.

background: imatinib mesylate is the first generation of tyrosine kinase inhibitors (tki) and highly effective in the treatment of chronic myeloid leukemia (cml). we aimed to evaluate thyroid function at baseline and at 1, 3, 6 and 12 months after initiation of imatinib mesylate therapy in 20 newly diagnosed bcr-abl positive cml patients. methods: this study was done during 2013-2014, 20 new ca...

The pharmacological control of intraocular pressure (IOP) is as complex as any other physiological system. The influence of the parasympathetic side of the autonomic nervous system, acting through muscarinic cholinergic receptors, has long been known, and cholinergic agonists such as pilocarpine are widely used in treatment of glaucoma. The sympathetic nervous system influences IOP in a remarka...

Previous studies have found that bromocriptine, cyproheptadine, and valproic acid can reduce ACTH secretion in Nelson's syndrome, but none of these agents has achieved widespread use due to their failure to normalize ACTH in most patients. The current study was undertaken to determine whether these three agents, which act through different mechanisms, decrease plasma ACTH synergistically when a...